Heart and lung scans and blood tests after chest radiotherapy
Tests heart and lung scans with blood markers in adults at risk after radiotherapy.
Plain-language title generated from the registry record
Registry title: PET/MR Pre- and Post Radiotherapy for Cardiopulmonary Dysfunction Evaluation
Key facts
- Where
- Toronto, CanadaSee the site
Where in Canada
- University Health NetworkToronto, CanadaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Health Network, Toronto
- Trial code
- NCT04901884
- Record updated
- 5 October 2026
- Original description
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.Read full original descriptionShow less
Exploratory Evaluation of Simultaneous Cardiac PET/MR, Metabolomic Markers and Circulating DNA as Possible Prognostic Markers in Identifying Patients Developing Transient or Permanent Cardiopulmonary Dysfunctions After Radiotherapy
Radiotherapy (RT) is a well-known and established therapy or adjuvant therapy for the treatment of thoracic cancer It uses a high energy radiation from x-rays, gamma rays and other charged particles that assist in damaging the cancer DNA.
PET/MR as imaging biomarkers for cardiopulmonary dysfunction with a focus on Pulmonary hypertension (PH).
Despite the measures taken to reduce the total radiation dose and to limit the radiation to normal tissues, there is evidence of transient or permanent radiotherapy induced myocardial and pulmonary dysfunction leading to PH in patients who receive radiotherapy above a certain threshold of received dose.
To be able to Demonstrate correlation of combined PET/MR and plasma metabolomics markers in patients at risk of developing cardiopulmonary disfunction after RT.
Inclusion: Age ≥18 years; Biopsy or otherwise clinically proven thoracic malignant mass which is intended to be treated with radio(chemo)therapy; Intention to treat with radio(chemo)therapy with incidental cardiac irradiation of at least 25Gy; A negative urine or serum pregnancy test within the two week interval immediately prior to imaging, in women of child-bearing age; Ability to provide written informed consent to participate in the study (for all components of the trial: imaging with cardiac PET/MR, blood sampling for plasma metabolomics and circulating DNA).
Exclusion: Any patient with known hypersensitivity to 18F-FDG; Contraindication for MR as per current institutional guidelines; Contraindication for Gadolinium injection as per current institutional guidelines; Inability to lie supine for at least 45 minutes; Any patient who is pregnant or breastfeeding.